CSPC Pharmaceutical Group and Daehwa Pharmaceutical both invested in a round that will be used to take Haihe's anti-tumour therapies further down the clinical path.

China-based cancer therapy developer Haihe Biopharma raised $146.6m yesterday in a funding round featuring drug producers CSPC Pharmaceutical Group and Daehwa Pharmaceutical. Huagai Capital, Yingke PE, Hillhouse Capital, Atlas Capital, BioTrack Capital, Elite Capital and Chinese Academy of Sciences Venture Capital Management Co, which invests on behalf of the eponymous research organisation, also participated in…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.